STOK NASDAQ
Stoke Therapeutics, Inc.
1W: +3.3%
1M: -16.0%
3M: -21.0%
YTD: -17.1%
1Y: +8.6%
3Y: +556.9%
5Y: -1.5%
$25.62
-0.39 (-1.50%)
Weekly Expected Move ±7.2%
$22
$24
$26
$27
$29
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
5 relationships5
As Filer
counterparties named
0
As Counterparty
mentioned by others
2
Rel. Types
2022-01-10
Earliest Filing
2025-02-18
Latest Filing
partner: 4
supplier: 1
Counterparties (Filed by STOK)
5 relationshipsCompanies named in STOK's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Biogen International GmbH | BIIB | partner | Entered into a License and Collaboration Agreement for the development and commercialization of zorevunersen (STK-001) o | 2025-02-18 | View |
| Xenon Property, LLC | — | supplier | Lease agreement counterparty for corporate headquarters and laboratory lease extension | 2023-12-14 | View |
| Cantor Fitzgerald & Co. | — | partner | Entered into a Controlled Equity Offering Sales Agreement to act as sales agent or principal for the Company's ATM offer | 2022-05-20 | View |
| Stifel, Nicolaus & Company, Incorporated | — | partner | Terminated its existing Controlled Equity Offering Sales Agreement with the Company effective upon the effectiveness of | 2022-05-20 | View |
| Acadia Pharmaceuticals Inc. | ACAD | partner | Entered into a License and Collaboration Agreement for the discovery, development, and commercialization of novel RNA-ba | 2022-01-10 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-09-25 | Officer/Director Change | View | |
| 2026-08-03 | Earnings Release; Exhibits | View | |
| 2026-08-03 | Other Events; Exhibits | View | |
| 2026-06-30 | Regulation FD; Other Events; Exhibits | View | |
| 2026-06-04 | Shareholder Vote | View | |
| 2026-05-07 | Earnings Release; Exhibits | View | |
| 2026-04-07 | Officer/Director Change; Regulation FD; Exhibits | View | |
| 2026-03-27 | Accountant Change; Exhibits | View | |
| 2026-03-03 | Departure/Election of Directors; Appointment of Officers | View | |
| 2026-01-26 | Entry into Material Definitive Agreement; Creation of Direct Financial Obligation | Agreement | View |
| 2026-01-12 | Results of Operations and Financial Condition; Regulation FD Disclosure; Other Events; Financial Sta | View | |
| 2025-12-05 | Regulation FD Disclosure; Other Events; Financial Statements and Exhibits | View | |
| 2025-11-04 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-10-06 | Departure/Election of Directors; Appointment of Officers; Financial Statements and Exhibits | View | |
| 2025-09-18 | Submission of Matters to a Vote of Security Holders | View | |
| 2025-08-12 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2025-08-11 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2025-07-10 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2025-06-04 | Regulation FD Disclosure; Other Events; Financial Statements and Exhibits | View | |
| 2025-06-04 | Submission of Matters to a Vote of Security Holders | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR